http://www.cancernet...satinib-use-cml
Notably, drug-related pleural effusion was more common with dasatinib, occurring in 28% compared with 0.8% of imatinib patients. The authors noted that pleural effusion did not impair patients' ability to obtain a response.
"These results suggest that first-line dasatinib should continue to be considered a standard first-line therapy for patients with newly diagnosed chronic phase CML," the authors concluded, adding that other randomized studies have confirmed the benefit of dasatinib as well.